SG11201912865VA - Multi-specific antibodies and methods of making and using thereof - Google Patents

Multi-specific antibodies and methods of making and using thereof

Info

Publication number
SG11201912865VA
SG11201912865VA SG11201912865VA SG11201912865VA SG11201912865VA SG 11201912865V A SG11201912865V A SG 11201912865VA SG 11201912865V A SG11201912865V A SG 11201912865VA SG 11201912865V A SG11201912865V A SG 11201912865VA SG 11201912865V A SG11201912865V A SG 11201912865VA
Authority
SG
Singapore
Prior art keywords
making
methods
specific antibodies
antibodies
specific
Prior art date
Application number
SG11201912865VA
Other languages
English (en)
Inventor
Yi Zhu
Ole Olsen
Dong Xia
David Jellyman
Katrina Bykova
Anne-Marie Rousseau
Bill Brady
Blair Renshaw
Brian Kovacevich
Yu Liang
Zeren Gao
Original Assignee
Systimmune Inc
Sichuan Baili Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Systimmune Inc, Sichuan Baili Pharmaceutical Co Ltd filed Critical Systimmune Inc
Publication of SG11201912865VA publication Critical patent/SG11201912865VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201912865VA 2017-06-25 2018-06-22 Multi-specific antibodies and methods of making and using thereof SG11201912865VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762524558P 2017-06-25 2017-06-25
PCT/US2018/039157 WO2019005640A2 (en) 2017-06-25 2018-06-22 MULTISPECIFIC ANTIBODIES AND METHODS OF MAKING AND USING SAME

Publications (1)

Publication Number Publication Date
SG11201912865VA true SG11201912865VA (en) 2020-01-30

Family

ID=64742656

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201912865VA SG11201912865VA (en) 2017-06-25 2018-06-22 Multi-specific antibodies and methods of making and using thereof

Country Status (10)

Country Link
US (1) US20200157224A1 (https=)
EP (1) EP3645048A4 (https=)
JP (2) JP7474193B2 (https=)
KR (1) KR102838340B1 (https=)
CN (3) CN117946278A (https=)
AU (1) AU2018295119B2 (https=)
CA (1) CA3068049A1 (https=)
IL (1) IL271260B1 (https=)
SG (1) SG11201912865VA (https=)
WO (1) WO2019005640A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250376531A9 (en) * 2017-06-25 2025-12-11 Systimmune, Inc. Anti-4-1bb antibodies and methods of making and using thereof
CN116948035A (zh) * 2017-06-25 2023-10-27 西雅图免疫公司 多特异性抗体及其制备和使用方法
CN110799538B (zh) * 2017-08-28 2023-08-01 西雅图免疫公司 抗cd3抗体及其制备和使用方法
US20210008113A1 (en) * 2018-03-27 2021-01-14 Systimmune, Inc. Methods of making and using guidance and navigation control proteins
CN114786730A (zh) 2019-11-05 2022-07-22 再生元制药公司 N-端scFv多特异性结合分子
CN114502203B (zh) * 2019-11-06 2024-07-19 成都百利多特生物药业有限责任公司 制导和导航控制蛋白及其制备和使用方法
EP4097135A4 (en) * 2020-01-31 2024-07-03 Gensun Biopharma Inc. Bispecific t cell engagers
TWI874613B (zh) * 2020-03-17 2025-03-01 美商西雅圖免疫公司 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
EP3988568A1 (en) * 2020-10-21 2022-04-27 Numab Therapeutics AG Combination treatment
JP2024523838A (ja) * 2021-06-09 2024-07-02 シャンハイ エピムアブ バイオセラピューティクス カンパニー リミテッド Ｏｘ４０及び／又はｐｄ－ｌ１に結合する抗体及び二重特異性結合タンパク質
TWI833244B (zh) * 2021-06-18 2024-02-21 大陸商和鉑醫藥（上海）有限責任公司 一種雙抗組合及其應用
JP2025512953A (ja) * 2022-04-11 2025-04-22 アストラゼネカ・アクチエボラーグ Ｔ細胞結合タンパク質
WO2024160721A1 (en) 2023-01-30 2024-08-08 Kymab Limited Antibodies
CN118667026A (zh) * 2023-03-15 2024-09-20 三生国健药业（上海）股份有限公司 抗muc17*cd3*cd28三特异性抗体

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ302070B6 (cs) 1998-04-21 2010-09-29 Micromet Ag Jednoretezcový multifunkcní polypeptid, polynukleotid, vektor obsahující tento polynukleotid, bunka transfekovaná tímto polynukleotidem, prostredek obsahující tento polypeptid, polynukleotid nebo vektor a jejich použití a zpusob identifikace aktiváto
WO2007002223A2 (en) * 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
WO2008119565A2 (en) * 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific binding domain
RS53008B2 (sr) * 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
US8178101B2 (en) * 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
LT3216803T (lt) * 2008-06-25 2020-06-10 Novartis Ag Stabilūs ir tirpūs antikūnai, slopinantys vegf
TW201100543A (en) * 2009-05-27 2011-01-01 Hoffmann La Roche Tri-or tetraspecific antibodies
CA2854806A1 (en) * 2011-11-07 2013-05-16 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
EP3013864A1 (en) * 2013-06-26 2016-05-04 Numab AG Novel antibody frameworks
CN105722859B (zh) * 2013-07-25 2021-05-07 西托姆克斯治疗公司 多特异性抗体、多特异性可活化抗体及其使用方法
EP3327038B1 (en) * 2013-12-20 2020-09-23 F. Hoffmann-La Roche AG Bispecific her2 antibodies and methods of use
CA2940242C (en) * 2014-02-20 2026-01-13 H. Lundbeck A/S Anti-acth antibodies and use thereof
UA117289C2 (uk) * 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
EP3149042B1 (en) * 2014-05-29 2019-08-28 Spring Bioscience Corporation Pd-l1 antibodies and uses thereof
WO2016016299A1 (en) * 2014-07-29 2016-02-04 F. Hoffmann-La Roche Ag Multispecific antibodies
WO2016105450A2 (en) * 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
EP3253790A4 (en) * 2015-02-06 2018-07-25 University of Maryland, Baltimore Tetra-specific, octameric binding agents and antibodies against clostridium difficile toxin a and toxin b for treatment of c. difficile infection
PH12017501857B1 (en) 2015-06-16 2024-01-17 Merck Patent Gmbh Pd-l1 antagonist combination treatments
WO2017011342A1 (en) * 2015-07-10 2017-01-19 Abbvie Inc. Igm-or-ige-modified binding proteins and uses thereof
JP6932700B2 (ja) * 2015-09-15 2021-09-08 アムジエン・インコーポレーテツド ４価の二重特異性抗原結合タンパク質及び４価の四重特異性抗原結合タンパク質、ならびにそれらの使用
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
EP3156417A1 (en) * 2015-10-13 2017-04-19 Affimed GmbH Multivalent fv antibodies
CN106397598B (zh) * 2016-02-23 2020-07-14 上海交通大学 多价多特异性抗体及免疫杂合蛋白的表达和制备方法
CN116948035A (zh) * 2017-06-25 2023-10-27 西雅图免疫公司 多特异性抗体及其制备和使用方法
US20210008113A1 (en) * 2018-03-27 2021-01-14 Systimmune, Inc. Methods of making and using guidance and navigation control proteins

Also Published As

Publication number Publication date
IL271260A (en) 2020-01-30
CN117946277A (zh) 2024-04-30
CN110799540B (zh) 2024-02-13
JP2024105268A (ja) 2024-08-06
JP7474193B2 (ja) 2024-04-24
RU2020102663A (ru) 2021-07-27
NZ760935A (en) 2024-11-29
CN110799540A (zh) 2020-02-14
EP3645048A4 (en) 2021-06-16
CA3068049A1 (en) 2019-01-03
IL271260B1 (en) 2026-02-01
KR20200092302A (ko) 2020-08-03
RU2020102663A3 (https=) 2022-04-06
WO2019005640A2 (en) 2019-01-03
CN117946278A (zh) 2024-04-30
AU2018295119B2 (en) 2024-10-03
JP7685095B2 (ja) 2025-05-28
JP2020530306A (ja) 2020-10-22
US20200157224A1 (en) 2020-05-21
AU2018295119A1 (en) 2020-02-06
WO2019005640A3 (en) 2019-02-07
EP3645048A2 (en) 2020-05-06
KR102838340B1 (ko) 2025-07-24

Similar Documents

Publication Publication Date Title
SG11201912865VA (en) Multi-specific antibodies and methods of making and using thereof
ZA201906730B (en) Anti-trem2 antibodies and methods of use thereof
SG11201912864SA (en) Multi-specific antibodies and methods of making and using thereof
IL275070A (en) FCRN antibodies and methods of using them
PL3618863T3 (pl) Przeciwciała anty- tigit i sposoby ich zastosowania
IL259495A (en) Antibodies and methods for using them
IL256086A (en) Anti-her2 antibodies and methods of use
IL254887A0 (en) Anti-sortilin antibodies and methods of using them
IL252837B (en) fcrn antibodies and methods of using them
SG10201912150TA (en) Anti-trem2 antibodies and methods of use thereof
IL259681A (en) New antibodies against claudin and methods of using them
IL270793A (en) Anti-HTRA1 antibodies and methods of using them
IL274221A (en) Antibodies to ANTI-APOC3 and methods of use
SG11202003237QA (en) Bispecific antibodies and methods of making and using thereof
ZA202002144B (en) Antibodies and methods of use
SMT202300278T1 (it) Anticorpi monoclonali anti cimici da letto, metodi di produzione e usi
IL275493A (en) Antibodies to centrin-1, methods for their preparation and use
AU2015901092A0 (en) PAT-SM3 related antibodies and methods of making and using same
AU2014901301A0 (en) PAT-SM3 related antibodies and methods of making and using same